Literature DB >> 27288434

DNA methylation in adult diffuse gliomas.

Veronique G LeBlanc, Marco A Marra.   

Abstract

Adult diffuse gliomas account for the majority of primary malignant brain tumours, and are in most cases lethal. Current therapies are often only marginally effective, and improved options will almost certainly benefit from further insight into the various processes contributing to gliomagenesis and pathology. While molecular characterization of these tumours classifies them on the basis of genetic alterations and chromosomal abnormalities, DNA methylation patterns are increasingly understood to play a role in glioma pathogenesis. Indeed, a subset of gliomas associated with improved survival is characterized by the glioma CpG island methylator phenotype (G-CIMP), which can be induced by the expression of mutant isocitrate dehydrogenase (IDH1/2). Aberrant methylation of particular genes or regulatory elements, within the context of G-CIMP-positive and/or negative tumours, has also been shown to be associated with differential survival. In this review, we provide an overview of the current knowledge regarding the role of DNA methylation in adult diffuse gliomas. In particular, we discuss IDH mutations and G-CIMP, MGMT promoter methylation, DNA methylation-mediated microRNA regulation and aberrant methylation of specific genes or groups of genes.
© The Author 2016. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  CIMP; DNA methylation; IDH mutations; MGMT promoter methylation; glioma

Mesh:

Year:  2016        PMID: 27288434     DOI: 10.1093/bfgp/elw019

Source DB:  PubMed          Journal:  Brief Funct Genomics        ISSN: 2041-2649            Impact factor:   4.241


  7 in total

1.  Long non-coding RNA GAS5, by up-regulating PRC2 and targeting the promoter methylation of miR-424, suppresses multiple malignant phenotypes of glioma.

Authors:  Chen Jin; Jie Zhao; Zhi-Ping Zhang; Ming Wu; Jian Li; Ge-Lei Xiao; Bo Liu; Yu-Xiang Liao; Jing-Ping Liu
Journal:  J Neurooncol       Date:  2020-05-29       Impact factor: 4.130

2.  Bioinformatic analysis of gene expression and methylation regulation in glioblastoma.

Authors:  Wen Wang; Zheng Zhao; Fan Wu; Haoyuan Wang; Jiangfei Wang; Qing Lan; Jizong Zhao
Journal:  J Neurooncol       Date:  2017-11-22       Impact factor: 4.130

Review 3.  Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications.

Authors:  Tathiane M Malta; Camila F de Souza; Thais S Sabedot; Tiago C Silva; Maritza S Mosella; Steven N Kalkanis; James Snyder; Ana Valeria B Castro; Houtan Noushmehr
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

4.  IGF2BP2 Induces U251 Glioblastoma Cell Chemoresistance by Inhibiting FOXO1-Mediated PID1 Expression Through Stabilizing lncRNA DANCR.

Authors:  Junfei Han; Xiaojun Yu; Shanxi Wang; Yingguang Wang; Qikun Liu; Haoran Xu; Xiaosong Wang
Journal:  Front Cell Dev Biol       Date:  2022-01-24

5.  MD2 Is a Potential Biomarker Associated with Immune Cell Infiltration in Gliomas.

Authors:  Mengya Zhao; Xiaodong Li; Yijun Chen; Shuzhen Wang
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244

6.  Retinol binding protein 1-dependent activation of NF- κB signaling enhances the malignancy of non-glioblastomatous diffuse gliomas.

Authors:  Wei Wu; Yichang Wang; Chen Niu; Alafate Wahafu; Longwei Huo; Xiaoye Guo; Jianyang Xiang; Xiaodong Li; Wanfu Xie; Xiaobin Bai; Maode Wang; Jia Wang
Journal:  Cancer Sci       Date:  2021-12-15       Impact factor: 6.716

7.  SNHG3 Affects Gastric Cancer Development by Regulating SEPT9 Methylation.

Authors:  Wei Li; Xudong Ma; Feng Wang; Shi Chen; Qingxiong Guo; Feng Sun; Yongqing Duan
Journal:  J Oncol       Date:  2022-04-28       Impact factor: 4.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.